Genuity Science
Accelerating Discovery in CNS, Cardiometabolic and Inflammatory Disease. We support our clients to achieve more in their target & biomarker programs. Our expertise, curated & disease enriched clinco-omic cohorts, tools and applications for insight generation, enable our clients to prioritize and accelerate discovery research & development. Robust, disease-specific datasets in CNS, Cardiometabolic and Inflammatory Disease are powered for statistical significance with multi-omic and whole genome data and detailed longitudinal clinical data.
Company details
Find locations served, office locations
- Business Type:
- Software vendor
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2013
- Employees:
- 11-100
About Us
Powering deeper discovery
Robust, disease-specific datasets in CNS, Cardiometabolic and Inflammatory Disease are powered for statistical significance with multi-omic and whole genome data and detailed longitudinal clinical data.
Accelerating drug target identification, validation, and biomarker discovery
Our disease-specific clinico-omic datasets in CNS, Cardiometabolic and Inflammatory Disease offer genomic data enriched with detailed clinical data and are statistically powered to enhance discovery.
Population Genomics Curated, disease specific, longitudinal deep phenotyped, genomic cohorts in CNS, cardiometabolic and inflammatory disease. Selected cohorts are distinguished by extensive clinical phenotyping, and the highest quality genomic data generation through our purpose-built CAP accredited genomics centre.
Population Multi-Omics The availability of focused multi-omic sub-cohorts to each of our population genomic cohorts enable our clients to combine genetic evidence with biological function to further establish causality and effect.
Powerful analytics crafted for insights Analytics and AI trained on multi-omic and phenotypic data. Proven in target discovery, drug response signatures and population genomics.
Our Capabilities & Expertise
- Target Discovery: Identify novel targets with strong genetic evidence.
- Portfolio Optimization: Validate candidate targets or biomarkers and focus investment
- Clinical Trials: Design better studies and enrollment criteria by identifying relevant sub-populations
- Biomarker Discovery: Discover novel biomarkers that enable higher resolution disease stratification
Global Disease Datasets
- Alzheimer's
- Diabetic and Non-diabetic Nephropathy
- Heart Failure
- Inflammatory Bowel Disease
- Liver Disease
- Lupus
- Multiple Sclerosis
- Parkinson's